Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
Author:
Affiliation:
1. University of Virginia Health Systems; UVA Digestive Health Center of Excellence; Box 800708 Charlottesville VA USA 22908
2. Center for Inflammatory Bowel Diseases; Virginia Commonwealth University Health System Box 980341 Richmond VA USA 23298
Publisher
Wiley
Subject
Pharmacology (medical)
Reference48 articles.
1. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial;Colombel;Gastroenterology,2007
2. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial;Feagan;Aliment Pharmacol Ther,2006
3. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002
4. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease;Rutgeerts;Gastroenterology,1999
5. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial;Sandborn;Gastroenterology,2001
Cited by 171 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Multipotent Human Neonatal Cardiac‐Derived Mesenchymal Stem Cells Modulate Ileitis In Vivo;Advanced Therapeutics;2023-07-12
2. Results of the Eighth Scientific Workshop of ECCO: Prevention and Treatment of Postoperative Recurrence in Patients With Crohn’s Disease Undergoing an Ileocolonic Resection With Ileocolonic Anastomosis;Journal of Crohn's and Colitis;2023-04-18
3. Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease;Frontiers in Microbiology;2023-02-23
4. Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease;World Journal of Gastroenterology;2022-08-14
5. Conventional Therapies for Crohn's Disease;Gastroenterology Clinics of North America;2022-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3